Viralgen and Trogenix to progress gene therapy for glioblastoma
Contract development and manufacturing organisation (CDMO) Viralgen has partnered biotech company Trogenix to accelerate the development of a recombinant adeno-associated…
Oncology
-
-
BioVaxys and Sona partner to develop cancer therapeutics
BioVaxys Technology and Sona Nanotech have signed a research agreement to develop cancer therapeutics utilising the former’s DPX immune educating…
-
EC approves AstraZeneca’s Calquence combo to treat MCL
The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), plus bendamustine and rituximab, to treat…
-
Veraxa and OmniAb to develop bispecific ADC tumour programme
Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate (bsADC) programme aimed…
-
TAE Life Sciences, Ohio State University partner to advance cancer drug development
TAE Life Sciences (TLS) has signed a letter of intent with the Ohio State University Comprehensive Cancer Center – Arthur…
-
Chinese regulator grants priority review for InnoCare’s solid tumour treatment
China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma's zurletrectinib (ICP-723)…
-
New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in…
-
GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led…
-
AstraZeneca’s Truqap fails in another Phase III trial
AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to…
-
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma
The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic (linvoseltamab) for adults with relapsed…
